Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging

Abstract

Get full access to this article

View all access options for this article.

References

Arrambide

Rovira

Sastre-Garriga

et al . Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler 2018; 24(3): 301–312.

Galassi

Prosperini

Logoteta

et al . A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. Mult Scler Relat Disord 2016; 8: 99–106.

Schlaeger

Papinutto

Panara

et al . Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014; 76(4): 568–580.

Wattjes

Rovira

Miller

et al .; MAGNIMS Study Group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis – establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11(10): 597–606.

Montalban

Hauser

Kappos

et al .; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209–220.

Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging – Commentary

Abstract

Get full access to this article

References